BackPrecision Peptide Company Overview

Precision Peptide Company Other Current Liabilities

Precision Peptide Company's other current liabilities is $29K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$29165.00

Peer trimmed avg / median

Loading

Precision Peptide Company Other Current Liabilities History

Loading

Precision Peptide Company vs. peers: Other Current Liabilities Comparison

Loading

Precision Peptide Company Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Precision Peptide Company (BPC.CN) FAQ

Precision Peptide Company (BPC.CN) currently reports a other current liabilities of $29K as of July 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Precision Peptide Company's other current liabilities history and peer comparisons.

Precision Peptide Company's other current liabilities changed from $0 to $29K (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Precision Peptide Company reported $29K in other current liabilities as of July 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $29K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Precision Peptide Company, and consider following BPC.CN for alerts when major investors trade the stock.